dc.date.accessioned | 2022-02-11T19:29:16Z | |
dc.date.available | 2022-02-11T19:29:16Z | |
dc.date.created | 2022-01-20T20:19:50Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Tøllefsen, Ingvild Maria Shetelig, Christian Seljeflot, Ingebjørg Eritsland, Jan Hoffmann, Pavel Andersen, Geir Øystein . High levels of interleukin-6 are associated with final infarct size and adverse clinical events in patients with STEMI. Open heart. 2021, 8(2), 1-9 | |
dc.identifier.uri | http://hdl.handle.net/10852/90844 | |
dc.description.abstract | Objective Inflammation has emerged as a new treatment target in patients with coronary artery disease and inflammation seems to play an important role in ischaemia/reperfusion injury that follows ST-elevation myocardial infarction (STEMI). We aimed to explore the role of acute and sustained interleukin 6 (IL-6) signalling, including soluble IL-6 receptor (IL-6R), with regard to infarct size, adverse remodelling and future cardiovascular events in patients with STEMI.
Methods We included 269 patients with first-time STEMI, symptom duration <6 hours and treated with percutaneous coronary intervention. Blood sampling and cardiac MRI were performed in the acute phase and after 4 months. Clinical events and all-cause mortality were registered during 12-month and 70-month follow-up, respectively.
Results IL-6 levels above median at all sampling points were significantly associated with increased infarct size and reduced left ventricular ejection fraction (LVEF). IL-6 levels in the highest quartile were at all sampling points associated with an increased risk of having an adverse clinical event during the first 12 months and with long-term all-cause mortality. IL-6R was not associated with infarct size, LVEF, myocardial salvage or long-term all-cause mortality.
Conclusion Acute and sustained elevation of IL-6 measured 4 months after STEMI were associated with larger infarct size, reduced LVEF and adverse clinical events including all-cause mortality. The results add important information to the sustained role of inflammation in patients with STEMI and IL-6 as a potential target for long-term intervention. | |
dc.language | EN | |
dc.publisher | BMJ Publishing Group | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | High levels of interleukin-6 are associated with final infarct size and adverse clinical events in patients with STEMI | |
dc.type | Journal article | |
dc.creator.author | Tøllefsen, Ingvild Maria | |
dc.creator.author | Shetelig, Christian | |
dc.creator.author | Seljeflot, Ingebjørg | |
dc.creator.author | Eritsland, Jan | |
dc.creator.author | Hoffmann, Pavel | |
dc.creator.author | Andersen, Geir Øystein | |
cristin.unitcode | 185,53,11,10 | |
cristin.unitname | Hjertemedisinsk avdeling | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 1986822 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Open heart&rft.volume=8&rft.spage=1&rft.date=2021 | |
dc.identifier.jtitle | Open heart | |
dc.identifier.volume | 8 | |
dc.identifier.issue | 2 | |
dc.identifier.doi | https://doi.org/10.1136/openhrt-2021-001869 | |
dc.identifier.urn | URN:NBN:no-93417 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 2053-3624 | |
dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/90844/1/T%25C3%25B8llefsen%2Bet%2Bal.pdf | |
dc.type.version | PublishedVersion | |
cristin.articleid | e001869 | |